Literature DB >> 23574382

The impact of haemarthropathy on the QoL of Korean severe haemophilia A patients: the critical level of haemarthropathy for the QoL.

C W You1.   

Abstract

The minimum goal of secondary prophylaxis may be to delay the progression of haemarthropathy below a critical level over which it has a great impact on the QoL of haemophilia patients. However, the critical level of haemarthropathy may be different across countries. For these reasons, the impact of haemarthropathy on the QoL in Korean haemophilia A patients was investigated. Depending on observed Pettersson scores of 27 severe haemophilia A patients, they were divided into three groups, P (Pettersson score) ≤ 10, P11~19 and P ≥ 20 groups. The QoL of each patient, assessed by the SF36, was compared between the groups. In addition, the changes in the QoL of the patients were observed according to the changes of Pettersson scores to find out the critical level of arthropathy. None of the scores of the SF36 scales were different between the P ≤ 10 and P11~19 groups. In contrast, the scores of PF and MH scales were significantly different between the P11~19 and P ≥ 20 groups. When changes in the scores of each scale in the SF36 were observed according to changes in Pettersson scores, the average P score of 13.0 ± 2.7 was thought to be the critical level of haemarthropathy because above that level, haemarthropathy and physical and mental health of the patients rapidly deteriorated. The progression of haemarthropathy to the critical level should be delayed as long as possible to prevent or to delay a rapid deterioration of the QoL of Korean patients with haemophilia.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23574382     DOI: 10.1111/hae.12131

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  3 in total

1.  Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product.

Authors:  Teruhisa Fujii; Hideji Hanabusa; Midori Shima; Takeshi Morinaga; Katsuyuki Fukutake
Journal:  Int J Hematol       Date:  2016-11-10       Impact factor: 2.490

Review 2.  Advances and challenges in hemophilic arthropathy.

Authors:  Tine Wyseure; Laurent O Mosnier; Annette von Drygalski
Journal:  Semin Hematol       Date:  2015-10-26       Impact factor: 3.851

3.  Health-Related Quality of Life and Association With Arthropathy in Greek Patients with Hemophilia.

Authors:  Agoritsa Varaklioti; Nick Kontodimopoulos; Dimitris Niakas; Anna Kouramba; Olga Katsarou
Journal:  Clin Appl Thromb Hemost       Date:  2017-10-09       Impact factor: 2.389

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.